WAVEMAN · COMPANY

ABBV · Abbvie Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ABBV

Name: AbbVie Inc. (ABBV) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

AbbVie Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001551152

CONGRESS · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$8.2M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

2,202

13F, latest reported quarter

REVENUE GROWTH

+8.6%

XBRL, annual

NET MARGIN

6.9%

CONVERSIONS · 180D

codes C/M, not in net · $2.6M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$8.2M over 180 days

-$8.2M over 90 days

below 83% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

2,202 funds added or opened last quarter

the highest in Pharma & Biotech

REVENUE

+8.6% year over year

more than 59% of Pharma & Biotech

MARGIN

6.9% net margin

more than 76% of Pharma & Biotech

BUYBACKS

$1.5B repurchased, FY to 2026-06-30

more than 95% of Pharma & Biotech

SHORT

1.3% of shares outstanding short · 4.0 days to cover · settled 2026-07-31

below 69% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

2,202 funds added or opened positions in the latest 13F quarter, of 4,219 holders.

1 member of Congress reported buying it this year.

3 trial completion dates slipped in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +24.8%

+24.8%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $8.2M sold by insiders over 180 days, 2,202 funds added last quarter, 1 Congress member(s) bought in 12 months, $8.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, AbbVie Inc. insiders sold a net $8.2M of stock across 148 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Donoghoe Nicholas

EVP, CHIEF BUS/STRAT OFFICER

SELL

2026-08-14

32,710.0

$8.2M

Purdue David Ryan

SVP, Controller

SELL

2026-03-04

5,230.0

$1.2M

Siatis Perry C

EVP, GC AND SECRETARY

SELL

2026-03-02

10,291.0

$2.4M

Siatis Perry C

EVP, GC AND SECRETARY

SELL

2026-03-02

2,600.0

$611.7K

Siatis Perry C

EVP, GC AND SECRETARY

SELL

2026-03-02

5,777.0

$1.3M

148 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 143 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

149,488,412.0 sh

$37.6B

VANGUARD CAPITAL MANAGEMENT LLC

115,396,098.0 sh

$29.0B

STATE STREET CORP

82,596,748.0 sh

$20.8B

VANGUARD PORTFOLIO MANAGEMENT LLC

48,477,996.0 sh

$12.2B

JPMORGAN CHASE & CO

47,862,796.0 sh

$12.2B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

NICHOLAS DONOGHOE

FILED 2026-08-14

$8.2M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Advisor Biotechnology Fund

$282.2M POSITION · AS OF 2026-04-30

14.8%

Select Biotechnology Portfolio

$707.7M POSITION · AS OF 2026-02-28

13.2%

Horizon Kinetics Medical ETF

$1.5M POSITION · AS OF 2026-03-31

8.4%

Biotechnology Fund

$796.2K POSITION · AS OF 2026-03-31

7.5%

Biotechnology Fund

$10.0M POSITION · AS OF 2026-03-31

7.4%

State Street(R) Health Care Select Sector SPDR(R) ETF

$2.8B POSITION · AS OF 2026-03-31

7.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 579 registered trials, 241 still enrolling or running — a status change here is dated weeks before the press release

144

Phase 1

52 ACTIVE

Phase 2

48 ACTIVE

157

Phase 3

63 ACTIVE

Phase 4

4 ACTIVE

135

Not applicable

54 ACTIVE

Multi-phase

20 ACTIVE

What changed recently

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

2026-09-05 · Completion moved 2023-09-06 → 2024-10-02

PHASE1,PHASE2

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Fe

2026-09-03 · Recruiting → Unknown

Phase 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficac

2026-09-03 · Completion moved 2026-03 → 2027-03

Phase 1

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult

2026-09-02 · Not Yet Recruiting → Recruiting

—

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves

2026-09-01 · Recruiting → Active Not Recruiting

Phase 1

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Event

2026-09-01 · Completion moved 2026-07 → 2026-08-04

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Abbvie Political Action Committee

CYCLE 2026 · $1,057K SPENT

$1.2M

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$61.2B	$56.3B	$54.3B	$58.1B
OPERATING INCOME	$15.1B	$9.1B	$12.8B	$18.1B
NET INCOME	$4.2B	$4.3B	$4.9B	$11.8B
EPS (DILUTED)	2.36	2.39	2.72	6.63
OPERATING CASH FLOW	$19.0B	$18.8B	$22.8B	$24.9B
CASH	$5.2B	$5.5B	$12.8B	$9.2B
LONG-TERM DEBT	$64.5B	$66.8B	$59.2B	$63.1B
BUYBACKS	$980.0M	$1.7B	$2.0B	$1.5B
DIVIDENDS PAID	$11.7B	$11.0B	$10.5B	$10.0B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE